<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01867606</url>
  </required_header>
  <id_info>
    <org_study_id>MC1267</org_study_id>
    <secondary_id>NCI-2013-00866</secondary_id>
    <secondary_id>MC1267</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT01867606</nct_id>
  </id_info>
  <brief_title>Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients With Gynecological Cancer After Undergoing Surgery</brief_title>
  <official_title>MC1267, A Randomized, Blinded Pilot Placebo-Controlled Trial With Oral Serum Bovine Immunoglobulin (SBI) to Assess Quality of Life and the Faster Post-Operative Recovery of Gynecological Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized pilot phase II trial studies how well serum bovine immunoglobulin protein
      isolate works in improving quality of life and post-operative recovery in patients with
      cancer of the female reproductive tract after undergoing surgery. Serum bovine immunoglobulin
      may help provide nutrition to patients who are not able to eat or digest ordinary food. This
      may improve the quality of life of patients with gynecological cancer and help them recover
      more quickly from surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare the time-to-quality of life (QOL) improvement from baseline in postoperative
      gynecological cancer patients who are receiving oral serum bovine immunoglobulin (SBI) vs.
      placebo.

      SECONDARY OBJECTIVES:

      I. To compare the surgical complication rates between oral SBI vs. placebo up to 1 month
      post-surgery (safety endpoint).

      II. To compare the QOL, as derived from the previously-validated Symptom Distress Scale, the
      Postoperative Quality of Life questionnaire (PQL), and the uniscale (overall QOL item)
      between patients receiving oral SBI vs. placebo.

      III. To compare the grade 2 or worse adverse event rates for patients receiving oral SBI vs.
      placebo.

      IV. To characterize the adverse event profile of oral SBI in postoperative gynecological
      cancer patients (safety endpoint).

      V. To compare supplement adherence between patients receiving oral SBI vs. placebo.

      TERTIARY OBJECTIVES:

      I. To explore whether candidate biomarkers are modified with SBI versus placebo.

      II. As part of ongoing research, to bank leftover blood samples for future studies.

      III. To explore quality of life during postoperative recovery after gynecologic surgery,
      regardless of whether or not patients take the study intervention/placebo or discontinue
      intervention/placebo early.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive SBI orally (PO) twice daily (BID) on days 1-28.

      ARM II: Patients receive placebo PO BID on days 1-28.

      In both arms, treatment repeats every 28 days for 3 courses in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">May 6, 2017</completion_date>
  <primary_completion_date type="Actual">November 21, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-to-QOL Improvement Defined as Any Increase in the QOL Score Measured Using the Total Score of the 14-item Postoperative Quality of Life (PQL) Tool</measure>
    <time_frame>up to 25 months</time_frame>
    <description>For this endpoint, the total QOL score could range from 1 to 140 (0 being the worst and 140 being the best). The primary analysis will be a comparison of oral SBI vs. placebo using a two-sided log-rank test between the 2 Kaplan-Meier curves.the total score of the 14-item Postoperative Quality of Life (PQL) tool [15] will be used, where the total score could range from 0 to 140 (0 being the worst and 140 being the best). These scores will be converted to the percentage scale, where a score of 140 will be converted to 100 and a score of 0 will remain as 0. This QOL will be measured weekly for the entire 12 week length of the study and at the end of the intervention. QOL improvement will be defined as at least a 10 point increase in the QOL score from baseline, on the percentage scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Adverse Event Rates for Grade 2 or Higher Adverse Events, Graded According to the Common Terminology Criteria for Adverse Events Version 4.0</measure>
    <time_frame>up to 25 months</time_frame>
    <description>Frequency tables will be reviewed to determine adverse event patterns, this data is reported in the adverse events section of this report. Below is the number of patients that experienced an adverse event greater than or equal to 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Complication Rates</measure>
    <time_frame>Up to 1 month post-surgery</time_frame>
    <description>Compared between the 2 arms using Chi-Square or Fisher's Exact tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention Compliance Assessed Using the Compliance Questionnaire</measure>
    <time_frame>up to 25 months</time_frame>
    <description>The frequency and percentage for each Compliance Questionnaire category will be summarized descriptively by cycle and by intervention arm. In addition, cycle by cycle compliance data will be compared between the 2 arms using a Chi-square test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QOL Measured Using the 14-item PQL Tool, Uniscale, and the Previously-validated Symptom Distress Scale</measure>
    <time_frame>up to 25 months</time_frame>
    <description>All 14 of the individual items from the PQL tool, along with the 4 additional items after the PQL questions will be analyzed and compared between the 2 intervention arms. Differences between post-randomization and baseline QOL scores will be analyzed and compared between the 2 arms using a Wilcoxon Rank-sum test. Also, other graphical and statistical methods will be used to compare the QOL between the 2 arms over time. For this endpoint, the total QOL score could range from 1 to 140 (0 being the worst and 140 being the best). These scores will be converted to the percentage scale, where a score of 140 will be converted to 100 and a score of 0 will remain as 0. This QOL will be measured weekly for the entire 12 week length of the study and at the end of the intervention. QOL improvement will be defined as at least a 10 point increase in the QOL score from baseline, on the percentage scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QOL in Patients Who do Not Start Intervention or Discontinue Early, Measured Using the 14-item PQL Tool, Uniscale, and the Previously-validated Symptom Distress Scale</measure>
    <time_frame>Baseline up to 25 months</time_frame>
    <description>Analysis will be descriptive in nature to see if these patients have a poorer QOL than patients who stay on study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Female Reproductive Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (serum-derived bovine immunoglobulin protein isolate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive SBI PO BID on days 1-28.
Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO BID on days 1-28.
Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>serum-derived bovine immunoglobulin protein isolate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (serum-derived bovine immunoglobulin protein isolate)</arm_group_label>
    <other_name>SBI</other_name>
    <other_name>serum bovine immunoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (serum-derived bovine immunoglobulin protein isolate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (serum-derived bovine immunoglobulin protein isolate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (serum-derived bovine immunoglobulin protein isolate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of gynecological cancer of any type or strong suspicion for cancer

          -  Patients must have begun postoperative oral intake of food prior to registration

          -  Open laparotomy or laparoscopic surgery undertaken with cancer therapeutic intent (not
             a subsequent surgery to manage a postoperative complication) that had occurred =&lt; 7
             days prior to registration and that entailed more than a simple hysterectomy

          -  Creatinine =&lt; 1.5 x the upper limit of normal (ULN)

          -  Absolute neutrophil count &gt;= 1500/mm^3

          -  Platelet count &gt;= 100,000/mm^3

          -  Ability to complete questionnaire(s) by themselves or with assistance

          -  Provide informed written consent

          -  Negative (serum) pregnancy test done =&lt; 7 days prior to randomization, for women of
             childbearing potential only

          -  Willing to provide mandatory baseline blood samples for correlative research purposes

        Exclusion Criteria:

          -  Symptomatic and/or untreated brain metastases

          -  Ongoing parenteral nutrition (receiving intravenous nutrition support at the time of
             enrollment); note: patients may be receiving maintenance intravenous (IV) fluids

          -  Current enrollment in any other trial that entails the concurrent administration of
             any other agent designed to enhance postoperative recovery

          -  Allergy to beef
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aminah Jatoi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>May 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <results_first_submitted>August 28, 2018</results_first_submitted>
  <results_first_submitted_qc>March 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 1, 2020</results_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Serum-derived Bovine Immunoglobulin Protein Isolate)</title>
          <description>Patients receive SBI PO BID on days 1-28. &gt;&gt;
&gt;&gt; Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. &gt;&gt;
&gt;&gt; serum-derived bovine immunoglobulin protein isolate: Given PO &gt;&gt;
&gt;&gt; laboratory biomarker analysis: Correlative studies &gt;&gt;
&gt;&gt; quality-of-life assessment: Ancillary studies &gt;&gt;
&gt;&gt; questionnaire administration: Ancillary studies</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO BID on days 1-28. &gt;&gt;
&gt;&gt; Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. &gt;&gt;
&gt;&gt; placebo: Given PO &gt;&gt;
&gt;&gt; laboratory biomarker analysis: Correlative studies &gt;&gt;
&gt;&gt; quality-of-life assessment: Ancillary studies &gt;&gt;
&gt;&gt; questionnaire administration: Ancillary studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled patients</population>
      <group_list>
        <group group_id="B1">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO BID on days 1-28. &gt;&gt;
&gt;&gt; Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. &gt;&gt;
&gt;&gt; placebo: Given PO &gt;&gt;
&gt;&gt; laboratory biomarker analysis: Correlative studies &gt;&gt;
&gt;&gt; quality-of-life assessment: Ancillary studies &gt;&gt;
&gt;&gt; questionnaire administration: Ancillary studies</description>
        </group>
        <group group_id="B2">
          <title>Arm I (Serum-derived Bovine Immunoglobulin Protein Isolate)</title>
          <description>Patients receive SBI PO BID on days 1-28. &gt;&gt;
&gt;&gt; Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. &gt;&gt;
&gt;&gt; serum-derived bovine immunoglobulin protein isolate: Given PO &gt;&gt;
&gt;&gt; laboratory biomarker analysis: Correlative studies &gt;&gt;
&gt;&gt; quality-of-life assessment: Ancillary studies &gt;&gt;
&gt;&gt; questionnaire administration: Ancillary studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="32" upper_limit="81"/>
                    <measurement group_id="B2" value="62" lower_limit="37" upper_limit="79"/>
                    <measurement group_id="B3" value="62" lower_limit="32" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-to-QOL Improvement Defined as Any Increase in the QOL Score Measured Using the Total Score of the 14-item Postoperative Quality of Life (PQL) Tool</title>
        <description>For this endpoint, the total QOL score could range from 1 to 140 (0 being the worst and 140 being the best). The primary analysis will be a comparison of oral SBI vs. placebo using a two-sided log-rank test between the 2 Kaplan-Meier curves.the total score of the 14-item Postoperative Quality of Life (PQL) tool [15] will be used, where the total score could range from 0 to 140 (0 being the worst and 140 being the best). These scores will be converted to the percentage scale, where a score of 140 will be converted to 100 and a score of 0 will remain as 0. This QOL will be measured weekly for the entire 12 week length of the study and at the end of the intervention. QOL improvement will be defined as at least a 10 point increase in the QOL score from baseline, on the percentage scale.</description>
        <time_frame>up to 25 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Serum-derived Bovine Immunoglobulin Protein Isolate)</title>
            <description>Patients receive SBI PO BID on days 1-28. &gt;
&gt;
&gt;
&gt;
&gt;
&gt; Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
&gt;
&gt;
&gt;
&gt;
&gt;
&gt; serum-derived bovine immunoglobulin protein isolate: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO BID on days 1-28. &gt;
&gt;
&gt;
&gt;
&gt;
&gt; Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
&gt;
&gt;
&gt;
&gt;
&gt;
&gt; placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-QOL Improvement Defined as Any Increase in the QOL Score Measured Using the Total Score of the 14-item Postoperative Quality of Life (PQL) Tool</title>
          <description>For this endpoint, the total QOL score could range from 1 to 140 (0 being the worst and 140 being the best). The primary analysis will be a comparison of oral SBI vs. placebo using a two-sided log-rank test between the 2 Kaplan-Meier curves.the total score of the 14-item Postoperative Quality of Life (PQL) tool [15] will be used, where the total score could range from 0 to 140 (0 being the worst and 140 being the best). These scores will be converted to the percentage scale, where a score of 140 will be converted to 100 and a score of 0 will remain as 0. This QOL will be measured weekly for the entire 12 week length of the study and at the end of the intervention. QOL improvement will be defined as at least a 10 point increase in the QOL score from baseline, on the percentage scale.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" lower_limit="3.0" upper_limit="6.43"/>
                    <measurement group_id="O2" value="3.29" lower_limit="2.43" upper_limit="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Adverse Event Rates for Grade 2 or Higher Adverse Events, Graded According to the Common Terminology Criteria for Adverse Events Version 4.0</title>
        <description>Frequency tables will be reviewed to determine adverse event patterns, this data is reported in the adverse events section of this report. Below is the number of patients that experienced an adverse event greater than or equal to 2.</description>
        <time_frame>up to 25 months</time_frame>
        <population>All evaluable patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Serum-derived Bovine Immunoglobulin Protein Isolate)</title>
            <description>Patients receive SBI PO BID on days 1-28. &gt;&gt;
&gt;&gt; Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
&gt;&gt;
&gt;&gt; serum-derived bovine immunoglobulin protein isolate: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO BID on days 1-28. &gt;&gt;
&gt;&gt; Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
&gt;&gt;
&gt;&gt; placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Adverse Event Rates for Grade 2 or Higher Adverse Events, Graded According to the Common Terminology Criteria for Adverse Events Version 4.0</title>
          <description>Frequency tables will be reviewed to determine adverse event patterns, this data is reported in the adverse events section of this report. Below is the number of patients that experienced an adverse event greater than or equal to 2.</description>
          <population>All evaluable patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgical Complication Rates</title>
        <description>Compared between the 2 arms using Chi-Square or Fisher's Exact tests.</description>
        <time_frame>Up to 1 month post-surgery</time_frame>
        <population>All evaluable patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Serum-derived Bovine Immunoglobulin Protein Isolate)</title>
            <description>Patients receive SBI PO BID on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Complication Rates</title>
          <description>Compared between the 2 arms using Chi-Square or Fisher's Exact tests.</description>
          <population>All evaluable patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Severe Complication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Complication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild Complication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Complication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intervention Compliance Assessed Using the Compliance Questionnaire</title>
        <description>The frequency and percentage for each Compliance Questionnaire category will be summarized descriptively by cycle and by intervention arm. In addition, cycle by cycle compliance data will be compared between the 2 arms using a Chi-square test.</description>
        <time_frame>up to 25 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Serum-derived Bovine Immunoglobulin Protein Isolate)</title>
            <description>Patients receive SBI PO BID on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. serum-derived bovine immunoglobulin protein isolate: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Intervention Compliance Assessed Using the Compliance Questionnaire</title>
          <description>The frequency and percentage for each Compliance Questionnaire category will be summarized descriptively by cycle and by intervention arm. In addition, cycle by cycle compliance data will be compared between the 2 arms using a Chi-square test.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <category_list>
                <category>
                  <title>Always to Usually Compliant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Occasionally to Never Compliant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Patient off treatment (NA)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <category_list>
                <category>
                  <title>Always to Usually Compliant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Occasionally to Never Compliant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Patient off treatment (NA)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in QOL Measured Using the 14-item PQL Tool, Uniscale, and the Previously-validated Symptom Distress Scale</title>
        <description>All 14 of the individual items from the PQL tool, along with the 4 additional items after the PQL questions will be analyzed and compared between the 2 intervention arms. Differences between post-randomization and baseline QOL scores will be analyzed and compared between the 2 arms using a Wilcoxon Rank-sum test. Also, other graphical and statistical methods will be used to compare the QOL between the 2 arms over time. For this endpoint, the total QOL score could range from 1 to 140 (0 being the worst and 140 being the best). These scores will be converted to the percentage scale, where a score of 140 will be converted to 100 and a score of 0 will remain as 0. This QOL will be measured weekly for the entire 12 week length of the study and at the end of the intervention. QOL improvement will be defined as at least a 10 point increase in the QOL score from baseline, on the percentage scale.</description>
        <time_frame>up to 25 months</time_frame>
        <population>All evaluable patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Serum-derived Bovine Immunoglobulin Protein Isolate)</title>
            <description>Patients receive SBI PO BID on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in QOL Measured Using the 14-item PQL Tool, Uniscale, and the Previously-validated Symptom Distress Scale</title>
          <description>All 14 of the individual items from the PQL tool, along with the 4 additional items after the PQL questions will be analyzed and compared between the 2 intervention arms. Differences between post-randomization and baseline QOL scores will be analyzed and compared between the 2 arms using a Wilcoxon Rank-sum test. Also, other graphical and statistical methods will be used to compare the QOL between the 2 arms over time. For this endpoint, the total QOL score could range from 1 to 140 (0 being the worst and 140 being the best). These scores will be converted to the percentage scale, where a score of 140 will be converted to 100 and a score of 0 will remain as 0. This QOL will be measured weekly for the entire 12 week length of the study and at the end of the intervention. QOL improvement will be defined as at least a 10 point increase in the QOL score from baseline, on the percentage scale.</description>
          <population>All evaluable patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in QOL in Patients Who do Not Start Intervention or Discontinue Early, Measured Using the 14-item PQL Tool, Uniscale, and the Previously-validated Symptom Distress Scale</title>
        <description>Analysis will be descriptive in nature to see if these patients have a poorer QOL than patients who stay on study.</description>
        <time_frame>Baseline up to 25 months</time_frame>
        <population>All evaluable patients who never started intervention or discontinue early. All patients completed the study, no patients are evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Serum-derived Bovine Immunoglobulin Protein Isolate)</title>
            <description>Patients receive SBI PO BID on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in QOL in Patients Who do Not Start Intervention or Discontinue Early, Measured Using the 14-item PQL Tool, Uniscale, and the Previously-validated Symptom Distress Scale</title>
          <description>Analysis will be descriptive in nature to see if these patients have a poorer QOL than patients who stay on study.</description>
          <population>All evaluable patients who never started intervention or discontinue early. All patients completed the study, no patients are evaluable for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 25 months</time_frame>
      <desc>The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 were utilized for AE reporting. Participants who did NOT withdraw (&quot;Withdrawal by Subject&quot;) from the study are included in this analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm II (Placebo)</title>
          <description>questionnaire administration: Ancillary studies</description>
        </group>
        <group group_id="E2">
          <title>Arm I (Serum-derived Bovine Immunoglobulin Protein Isolate)</title>
          <description>questionnaire administration: Ancillary studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E2" events="16" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="21" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" events="31" subjects_affected="14" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aminah Jatoi, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>(507) 284-4918</phone>
      <email>jatoi.aminah@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

